Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLMW NASDAQ:CDTTW NASDAQ:DRTSW NASDAQ:SXTPW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMWApollomics$0.01$0.01$0.00▼$0.05N/AN/A26,409 shs51,023 shsCDTTWConduit Pharmaceuticals$0.02+105.8%$0.01$0.01▼$0.02N/AN/A26,803 shs621 shsDRTSWAlpha Tau Medical$2.33+21.4%$1.41$0.20▼$2.99N/AN/A56,280 shs50,715 shsSXTPW60 Degrees Pharmaceuticals$0.04-1.8%$0.06$0.03▼$0.16N/AN/A12,759 shs1,243 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMWApollomics-17.73%-16.55%-36.96%-10.77%-42.00%CDTTWConduit Pharmaceuticals+22.02%-5.00%+77.10%+101.52%+24.30%DRTSWAlpha Tau Medical-18.30%-25.00%+43.71%+95.92%+814.29%SXTPW60 Degrees Pharmaceuticals-1.78%-15.90%-16.09%-3.02%-40.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMWApollomics$0.01$0.01$0.00▼$0.05N/AN/A26,409 shs51,023 shsCDTTWConduit Pharmaceuticals$0.02+105.8%$0.01$0.01▼$0.02N/AN/A26,803 shs621 shsDRTSWAlpha Tau Medical$2.33+21.4%$1.41$0.20▼$2.99N/AN/A56,280 shs50,715 shsSXTPW60 Degrees Pharmaceuticals$0.04-1.8%$0.06$0.03▼$0.16N/AN/A12,759 shs1,243 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMWApollomics-17.73%-16.55%-36.96%-10.77%-42.00%CDTTWConduit Pharmaceuticals+22.02%-5.00%+77.10%+101.52%+24.30%DRTSWAlpha Tau Medical-18.30%-25.00%+43.71%+95.92%+814.29%SXTPW60 Degrees Pharmaceuticals-1.78%-15.90%-16.09%-3.02%-40.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMWApollomics 0.00N/AN/AN/ACDTTWConduit Pharmaceuticals 0.00N/AN/AN/ADRTSWAlpha Tau Medical 0.00N/AN/AN/ASXTPW60 Degrees Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMWApollomics$8.50MN/AN/AN/AN/AN/ACDTTWConduit PharmaceuticalsN/AN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/AN/ASXTPW60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMWApollomicsN/AN/AN/AN/AN/AN/AN/AN/AN/ACDTTWConduit PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/AN/AN/AN/A8/18/2026 (Estimated)SXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMWApollomicsN/AN/AN/AN/AN/ACDTTWConduit PharmaceuticalsN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMWApollomicsN/ACDTTWConduit PharmaceuticalsN/ADRTSWAlpha Tau MedicalN/ASXTPW60 Degrees PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAPLMWApollomicsN/ACDTTWConduit PharmaceuticalsN/ADRTSWAlpha Tau MedicalN/ASXTPW60 Degrees PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMWApollomics59N/AN/ANot OptionableCDTTWConduit Pharmaceuticals7N/AN/ANot OptionableDRTSWAlpha Tau Medical80N/AN/ANot OptionableSXTPW60 Degrees Pharmaceuticals2N/AN/ANot OptionableCDTTW, SXTPW, DRTSW, and APLMW HeadlinesRecent News About These Companies60 Degrees Pharmaceuticals, Inc. Partners with Runway Health to Offer ARAKODA® for Convenient Online Malaria PreventionApril 15, 2026 | quiverquant.comQ60 Degrees Pharmaceuticals Reports 65% Increase in FY 2025 Net Product Revenues to $1.0 Million and Operational DevelopmentsMarch 31, 2026 | quiverquant.comQ60 Degrees Updates Affiliate Share Ownership Disclosure ErrorMarch 20, 2026 | tipranks.com60 Degrees Pharmaceuticals Updates Legal Opinion for ATM OfferingMarch 13, 2026 | tipranks.com60 Degrees Pharmaceuticals Regains Nasdaq Listing Compliance StatusFebruary 12, 2026 | tipranks.comGoodRx Partners with 60 Degrees Pharmaceuticals to Offer Up to 30% Savings on ARAKODA® for Malaria PreventionFebruary 2, 2026 | quiverquant.comQ60 Degrees Pharmaceuticals Faces Immediate Nasdaq Delisting AppealJanuary 23, 2026 | tipranks.com60 Degrees Pharmaceuticals Implements One-for-Four Reverse SplitJanuary 21, 2026 | tipranks.com60 Degrees Pharma outlines growth strategy in investor webinarJanuary 8, 2026 | tipranks.com60 Degrees Pharmaceuticals, Inc. Confirms Continuation of B-FREE Study to Assess ARAKODA® for Chronic Babesiosis TreatmentDecember 29, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Plans Expansion of Sales and Marketing Initiatives Following Positive Clinical Pilot ResultsDecember 11, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Launches First-Ever Study for Tafenoquine in Chronic Babesiosis PatientsNovember 21, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Faces Financial Challenges Amid Growth EffortsNovember 17, 2025 | tipranks.com60 Degrees Pharmaceuticals, Inc. Reports 223% Increase in Q3 2025 Net Product Revenue Despite Gross LossNovember 13, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Advances Tafenoquine Study for Chronic BabesiosisOctober 27, 2025 | tipranks.com60 Degrees Pharmaceuticals Submits Breakthrough Therapy Designation Request to FDA for Tafenoquine in Treating Relapsing BabesiosisOctober 15, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals unveils name of chronic babesiosis trialOctober 9, 2025 | msn.com60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis StudyOctober 9, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Launches B-FREE Chronic Babesiosis Study Following Patient Naming Competition and $5K Charity DonationOctober 9, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Highlights ARAKODA Growth PotentialSeptember 9, 2025 | tipranks.comMedia Sentiment Over TimeCDTTW, SXTPW, DRTSW, and APLMW Company DescriptionsApollomics NASDAQ:APLMW$0.01 0.00 (0.00%) As of 12:50 PM EasternApollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.Conduit Pharmaceuticals NASDAQ:CDTTW$0.02 +0.01 (+105.81%) As of 01:03 PM EasternConduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Alpha Tau Medical NASDAQ:DRTSW$2.33 +0.41 (+21.35%) As of 12:39 PM EasternAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.60 Degrees Pharmaceuticals NASDAQ:SXTPW$0.04 0.00 (-1.78%) As of 09:32 AM Eastern60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Build 2026 Is Really Just One Big AI Stress Test Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod MongoDB Is the Latest SaaS Apocalypse Victim to Say "Not Today" Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
